Lennox-Gastaut syndrome

Lennox–Gastaut syndrome (LGS) is a difficult-to-treat form of childhood-onset epilepsy that most often appears between the second and sixth year of life. LGS is characterized by a triad of signs including frequent seizures of multiple types, an abnormal EEG pattern of less than 2.5 Hz slow spike wave activity,

LGS children with a history of perinatal hypoxia or other perinatal event have earlier age of onset of seizures

Links

LGS may evolve from West syndrome

Endoscopic epilepsy surgery: Emergence of a new procedure

Surgical options for patients with Lennox-Gastaut syndrom epilepsia suppl. 55:21 4:21-8. doi: 10.1111/epi.12742.

• epileptic encephalopathy

Rufinamide

Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study

Clobazam

Archer et al. Ictal EEG features and peri-ictal SPECT of tonic seizures in LGS. Frontiers in Neurology 5 2014

Clobazam was approved by FDA on 2011 as adjuntive treatment of seizures associated with LGS in patients 2 year and older

Clobazam is equally safe and efficacious for seizures associated with Lennox–Gastaut syndrome across different age groups: Post hoc analyses of short- and long-term clinical trial results

stable dosage of clobazam for LGS are associated Epilepsia 55: 558(2014)

Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome

Assessment of treatment patterns and healthcare costs associated with probable Lennox–Gastaut syndrome

Disease classification WHO

G40.7 Lennox-Gastaut syndrome

ICD-10 online

  Interwiki via Wikidata